Proton pump inhibitors and colorectal cancer: A systematic review

doi:10.3748/wjg.v27.i44.7716

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 44

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7781)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

618

WORD

159

HTML

4200

Figures (1-1)

216

Tables (1-5)

241

Sum=5434

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

319

Download

618

Sum=937

Publishing Process of This Article

Item

Count

Browse

458

Download

952

Sum=1410

Nov 28, 2021 (publication date) through Jul 19, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Gastroenterol. Nov 28, 2021; 27(44): 7716-7733
Published online Nov 28, 2021. doi: 10.3748/wjg.v27.i44.7716

Full Size Figure Download Figure

Figure 1 Figure outlining areas for future research to establish a better understanding of the relationship between proton pump inhibitors and colorectal cancer. CapeOx: Capecitabine plus oxaliplatin; CRC: Colorectal cancer; DFS: Disease free survival; FOLFOX: Fluorouracil, leucovorin, oxaliplatin; 5-FU: 5-flourouracil; MFS: Metastasis free survival; OME: Omeprazole; OS: Overall survival; PAN: Pantoprazole; PPI: Proton pump inhibitors; RCT: Randomized controlled trials; RFS: Recurrence free survival; TOPK: T lymphokine–activated killer cell-originated protein kinase.

Citation: Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733
URL: https://www.wjgnet.com/1007-9327/full/v27/i44/7716.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i44.7716